MedTrace Logo

Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

NCT06544577 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2024-08-09

No results posted yet for this study

Summary

This study is a prospective non-interventional real-world study enrolling patients with advanced breast cancer who are ER+/HER2- and have ESR1- gene mutations, collecting information on patients' complaints, physical examination, laboratory tests, imaging tests and adverse events to observe the safety of elacestrant treatment.

Conditions

Interventions

DRUG

ELacestrant

345 mg/day once daily oral dosing

Sponsors & Collaborators

  • SciClone Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Qing Qu, Doctor · Ruijin Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-13
Primary Completion
2025-08-01
Completion
2026-08-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06544577 on ClinicalTrials.gov